West Pharmaceutical Says GLP-1 Surge Had 'Nothing One-Offish' — But Margins Are Not 'The New Floor'

West's CEO and CFO said GLP-1 sales growth had no one-time boost, and guided fourth-quarter revenue to $820 million to $830 million.

Share
West Pharmaceutical Says GLP-1 Surge Had 'Nothing One-Offish' — But Margins Are Not 'The New Floor'

West Pharmaceutical's management told analysts on the third-quarter earnings call on Thursday that its GLP-1 component surge had no one-time elements, with CEO Michele Lagarde saying there was "nothing one-offish in the quarter." CFO Bob McMahon added that GLP-1 high-value components grew "well into the 30s" organically and made up just under 12% of total revenue.

Pressed on one-time items

West Pharmaceutical, which makes containment and delivery systems for injectable drugs, was asked by an Evercore ISI analyst whether anything in the record GLP-1 elastomer quarter was a one-off. Lagarde called the drug class a durable growth driver. McMahon said management saw no one-time things, and pointed to the Medicare bridge program, generics outside the US and next-generation molecules as opportunities.

Total third-quarter revenue was $874 million, up 11.9% organically and 8.7% as reported. Adjusted earnings per share were $2.66, up 36% from a year earlier. High-value components revenue was $467 million, up 20% organically, and non-GLP-1 components grew in the high teens.

Margins: no floor, but more to come

A CJS Securities analyst asked whether the margin jump set a new floor. McMahon replied, "I wouldn't say that this is the new floor," adding that the quarter had no one-timers and that mix shift and strong volume showed the business's incremental margin strength.

Gross margin was 39.7%, up 310 basis points from a year earlier, and adjusted operating margin was 25.3%, up 420 basis points. McMahon called margin expansion "one of the underappreciated opportunities for us going forward" and said West is "not done with driving those margins over the next several years."

A cautious fourth-quarter guide

Management guided fourth-quarter revenue to $820 million to $830 million, or 6% to 7% organic growth, well below the third quarter's pace. McMahon called the guide prudent, saying it absorbs a stronger dollar and the third-quarter pull-forward in West Vantage, its contract-manufacturing segment.

For the full year, West raised revenue guidance to $3.41 billion to $3.42 billion, from $3.345 billion to $3.38 billion, and adjusted EPS to $9.38 to $9.48, from $8.85 to $9.05.

Next year, excluding SmartDose 3.5 revenue, which was $100 million this year, will create a roughly 290 basis point headwind to reported growth, McMahon said.

Capacity build and the February update

West is starting new investments in high-value finishing capacity in Europe and the US. Lagarde said such projects take 18 to 24 months to come online. McMahon said capital spending should stay within 6% to 8% of revenue, with 2026 at $215 million to $220 million.

West will give 2027 guidance with its fourth-quarter results in February.

West will give its first 2027 outlook in February, including how the new finishing capacity supports growth.

Sources

More on West Pharmaceutical

All West Pharmaceutical (WST) coverage →